Inspire Medical Systems (INSP) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q3 2025 revenue was $224.5 million, a 10% increase from $203.2 million in Q3 2024. U.S. revenue was $214.4 million (up 9%), while international revenue reached $10.1 million (up 37%).

Operating Income: $9.6 million, down from $14.3 million in the prior year.

Net Income: $9.9 million, compared to $18.5 million in Q3 2024, resulting in diluted earnings per share (EPS) of $0.34 (down from $0.60).

Adjusted EBITDA: $44 million, with a margin of 20%, down from 22% year-over-year.

Cash Position: Ended the quarter with $411 million in cash and investments; operating cash flow totaled $68.5 million for Q3.

2Strategic Updates and Business Highlights

Inspire V Launch: Significant progress with over 98% of physician training completed and over 75% of centers onboarding the Inspire V system. The device has shown improved patient outcomes and reduced surgical times.

Clinical Evidence: Positive data presented at ENT Society meetings, highlighting Inspire's effectiveness in treating obstructive sleep apnea (OSA) and its benefits over CPAP, particularly in reducing cardiovascular comorbidities.

Marketing Initiatives: Launched new advertising campaigns aimed at increasing patient awareness, including partnerships with influencers.

Reimbursement Updates: CMS finalized an 11% increase in reimbursement for CPT code 64568, effective January 1, 2026, which is expected to enhance the financial outlook for Inspire V.

3Forward Guidance and Outlook

2025 Revenue Guidance: Reaffirmed at $900 million to $910 million, representing 12% to 13% growth from 2024.

EPS Guidance: Increased to $0.90 to $1.00, up from a previous range of $0.40 to $0.50.

2026 Outlook: Early indications suggest revenue growth of 10% to 11%, with formal guidance to be provided in January 2026. The company expects to return to historical seasonality patterns in 2026.

4Bad News, Challenges, or Points of Concern

Operating Expenses: Total operating expenses increased by 17% year-over-year, primarily due to higher patient marketing costs and legal fees related to ongoing litigation.

Net Income Decline: The decline in net income and EPS compared to the previous year raises concerns about profitability amidst rising costs.

Competitive Pressures: While current competition is not seen as a significant headwind, the entry of new competitors into the market could pose future challenges.

Inventory Transition: The ongoing transition from Inspire IV to Inspire V may create temporary headwinds in inventory management and sales dynamics.

5Notable Q&A Insights

Market Dynamics: The management noted that the introduction of GLP-1 medications is driving more patients to seek sleep health evaluations, potentially increasing the patient pool for Inspire therapy.

Center Adoption: Over 75% of centers are now implanting Inspire V, but some continue to use Inspire IV due to economic considerations related to reimbursement rates.

Operational Efficiency: There are efforts to streamline operations and improve efficiency in territory management, which is expected to enhance profitability over time.

Future Growth: Management expressed confidence in the durability of growth driven by the Inspire V launch and increasing patient flow, while also acknowledging the need to monitor competitive dynamics closely. Overall, Inspire Medical Systems demonstrated solid financial performance in Q3 2025, with a strong focus on innovation and strategic marketing initiatives, while also navigating challenges related to operating expenses and competitive pressures.